June 20, 2011
Life value
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
STADA-VN has been acknowledged as one of the most prestigious enterprises on the domestic pharmaceutical market. Recently, STADA-VN has held a “Customer Conference” in Binh Duong province on 18 June 2011 in order to show the deep gratitude to closed partners and customers for their supports during the last time.
Over 200 doctors and pharmacists from hospitals, clinics, pharmacy stores and many agencies in Binh Duong province have attended the conference.
STELLAPHARM is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-viral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An Town, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com
The Ministry of Health has proposed a policy to encourage the transfer of new and innovative drugs, aiming to create more opportunities for patients. According to the ministry’s Drug Administration of Vietnam (DAV), innovative drugs in Vietnam account for only about 3% of the total but represent up to 22% of the value and are
A draft version of the revised Pharmacy Law will be presented to the ongoing National Assembly session to enhance public access to new medicines. Only 9% of new medicines have been introduced in Việt Nam over the past decade, far lower than that in other Asia-Pacific countries (20%). The Head of Legal and Integration Department